Aquestive Therapeutics Inc. has announced that multiple presentations related to its investigational product candidate Anaphylm™ (dibutepinephrine) sublingual film will be featured at the 2025 American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting, taking place November 6-10, 2025, in Orlando, FL. The presentations will include an oral session on Phase 1 evaluation of sublingual film pharmacokinetics, pharmacodynamics, safety, and tolerability in at-risk pediatric patients, as well as poster presentations on pharmacokinetics in adult and pediatric subjects and insights from clinician and caregiver surveys regarding unmet needs in anaphylaxis care. The results are scheduled to be presented at the ACAAI Annual Meeting, and abstracts will be made available online beginning November 6, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aquestive Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9564886-en) on October 30, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.